JP2011520810A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520810A5
JP2011520810A5 JP2011508593A JP2011508593A JP2011520810A5 JP 2011520810 A5 JP2011520810 A5 JP 2011520810A5 JP 2011508593 A JP2011508593 A JP 2011508593A JP 2011508593 A JP2011508593 A JP 2011508593A JP 2011520810 A5 JP2011520810 A5 JP 2011520810A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
cycloalkyl
substituted
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011508593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520810A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/042805 external-priority patent/WO2009137454A1/en
Publication of JP2011520810A publication Critical patent/JP2011520810A/ja
Publication of JP2011520810A5 publication Critical patent/JP2011520810A5/ja
Withdrawn legal-status Critical Current

Links

JP2011508593A 2008-05-06 2009-05-05 C型肝炎の治療のための7h−インドロ[2,1−a][2]ベンゾアゼピン−10−カルボン酸誘導体 Withdrawn JP2011520810A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5074308P 2008-05-06 2008-05-06
US61/050,743 2008-05-06
PCT/US2009/042805 WO2009137454A1 (en) 2008-05-06 2009-05-05 7h-indolo[2,1-a] [2] benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c

Publications (2)

Publication Number Publication Date
JP2011520810A JP2011520810A (ja) 2011-07-21
JP2011520810A5 true JP2011520810A5 (cg-RX-API-DMAC7.html) 2012-06-21

Family

ID=40786514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508593A Withdrawn JP2011520810A (ja) 2008-05-06 2009-05-05 C型肝炎の治療のための7h−インドロ[2,1−a][2]ベンゾアゼピン−10−カルボン酸誘導体

Country Status (19)

Country Link
US (1) US8133884B2 (cg-RX-API-DMAC7.html)
EP (1) EP2280975B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011520810A (cg-RX-API-DMAC7.html)
KR (1) KR20110015588A (cg-RX-API-DMAC7.html)
CN (1) CN102083834A (cg-RX-API-DMAC7.html)
AR (1) AR071684A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009244409A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0915130A2 (cg-RX-API-DMAC7.html)
CA (1) CA2723683A1 (cg-RX-API-DMAC7.html)
CL (1) CL2009001089A1 (cg-RX-API-DMAC7.html)
CO (1) CO6290645A2 (cg-RX-API-DMAC7.html)
EA (1) EA201001748A1 (cg-RX-API-DMAC7.html)
IL (1) IL208753A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010011921A (cg-RX-API-DMAC7.html)
NZ (1) NZ588556A (cg-RX-API-DMAC7.html)
PE (1) PE20091879A1 (cg-RX-API-DMAC7.html)
TW (1) TW200951135A (cg-RX-API-DMAC7.html)
WO (1) WO2009137454A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007649B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ATE531373T1 (de) 2008-03-27 2011-11-15 Bristol Myers Squibb Co Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080399A1 (ja) 2004-02-24 2005-09-01 Japan Tobacco Inc. 4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2007119562A (ru) 2004-10-26 2008-12-10 Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) Тетрациклические производные индолов в качестве противовирусных агентов
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
DE602007006796D1 (de) 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US7652004B2 (en) 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8129367B2 (en) 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C

Similar Documents

Publication Publication Date Title
JP2010521483A5 (cg-RX-API-DMAC7.html)
JP2010521476A5 (cg-RX-API-DMAC7.html)
JP2010521481A5 (cg-RX-API-DMAC7.html)
JP2010515752A5 (cg-RX-API-DMAC7.html)
JP2010521484A5 (cg-RX-API-DMAC7.html)
JP2008530096A5 (cg-RX-API-DMAC7.html)
JP2010510234A5 (cg-RX-API-DMAC7.html)
US8426458B2 (en) Hepatitis C Virus inhibitors
JP2012504632A5 (cg-RX-API-DMAC7.html)
JP2010535787A5 (cg-RX-API-DMAC7.html)
JP2011523651A5 (cg-RX-API-DMAC7.html)
US8420686B2 (en) Linked diimidazole antivirals
US8609648B2 (en) Hepatitis C virus inhibitors
ES2449540T3 (es) Inhibidores macrocíclicos del virus de la hepatitis C
HRP20120707T1 (hr) Spojevi za liječenje hepatitisa c
JP2012519173A5 (cg-RX-API-DMAC7.html)
JP2011521965A5 (cg-RX-API-DMAC7.html)
JP2012504132A5 (cg-RX-API-DMAC7.html)
JP2014522809A5 (cg-RX-API-DMAC7.html)
JP2012528161A5 (cg-RX-API-DMAC7.html)
HRP20110194T1 (hr) Ciklopropil fuzionirani indolobenzazepini kao inhibitori hcv ns5b
JP2013510853A5 (cg-RX-API-DMAC7.html)
JP2012522056A5 (cg-RX-API-DMAC7.html)
WO2007120595A2 (en) Amines for the treatment of hcv
JP2013514359A5 (cg-RX-API-DMAC7.html)